Volition Launches rNuQ™ Webshop Broadening Product Range

Volition (NYSE AMERICAN: VNRX) launched the rNuQ™ webshop on April 20, 2026, selling ready-to-use recombinant nucleosomes developed over the past 10 years.

Rhea-AI Summary

Volition (NYSE AMERICAN: VNRX) launched the rNuQ™ webshop on April 20, 2026, selling ready-to-use recombinant nucleosomes developed over the past 10 years.

Manufactured in an ISO 13485 facility, products ship at +4 °C in a glycerol-free buffer. The move expands Nu.Q® Discover commercialisation after 86% revenue growth in 2025 and ~100 clients worldwide.

Positive

• Nu.Q Discover revenue grew 86% in 2025
• ~100 clients served worldwide, including top pharma and diagnostics
• ISO 13485 manufacturing supports reproducibility and quality control
• rNuQ webshop provides direct online sales and faster access for researchers

Negative

• Webshop revenue impact is uncertain; described only as a potential new source
• No specific 2026 revenue guidance provided; company expects a similar trajectory only

Argus Apr 20 session

-8.72% close to close Open Argus

Details

News Market Reaction – VNRX

On Apr 20, the day this news came out, VNRX closed 8.72% below the previous close.

Data tracked by StockTitan Argus for the Apr 20 session.

Key Figures

Development period: 10 years Storage temperature: +4 °C Client count: close to 100 clients +2 more

Development period

10 years

Time spent developing recombinant nucleosomes for controls

Storage temperature

+4 °C

Nucleosomes stored and shipped at +4 °C

Client count

close to 100 clients

Nu.Q® Discover pillar customer base worldwide

Nu.Q Discover growth

86% revenue growth

Nu.Q® Discover revenue growth delivered in 2025

Growth outlook year

2026

Management anticipates similar Nu.Q® Discover trajectory in 2026

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Full-year earnings

   24h Move

   -1.0%

   Reported 2025 revenue growth and reduced losses with lower operating expenses.

2. Mar 31

   Non-dilutive funding

   24h Move

   +6.3%

   Secured €2.0M in Belgian regional non‑dilutive financing for Nu.Q® programs.

3. Mar 30

   Clinical study data

   24h Move

   -3.4%

   Mayo Clinic study showed elevated Nu.Q® markers in trauma patients and VTE risk.

4. Mar 26

   Conference abstract

   24h Move

   +0.9%

   ELCC abstract showed Nu.Q® assay stratifying prognosis in lung cancer patients.

5. Mar 25

   Earnings call setup

   24h Move

   +0.9%

   Scheduled full‑year 2025 earnings call and business update for investors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

recombinant nucleosomes, iso 13485, pharmacodynamic biomarkers, biospecimens, +1 more

5 terms

recombinant nucleosomes medical

"launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes"

Recombinant nucleosomes are lab-made copies of the basic units that package DNA in cells, assembled from purified proteins and DNA rather than taken from tissues. Investors should care because they are standardized research tools used to test how drugs, diagnostics, or gene-editing technologies interact with DNA packaging; like using a calibrated crash test dummy, they help predict efficacy, safety, and reproducibility before costly clinical steps.

iso 13485 regulatory

"Manufactured in an ISO 13485 certified facility, delivering exceptional reproducibility"

ISO 13485 is an international quality management standard for organizations that design, produce, or service medical devices. Think of it as a factory’s rulebook and checklist that helps ensure products are safe, consistently made, and meet regulatory rules worldwide. For investors, certification signals lower operational and regulatory risk, easier market access, and greater reliability of a company’s medical products and supply chain — similar to buying from a trusted, inspected supplier.

pharmacodynamic biomarkers medical

"late stage clinical trials using our assays as pharmacodynamic biomarkers."

Pharmacodynamic biomarkers are measurable signs that show whether a drug is affecting the body the way it’s supposed to — for example a change in a blood protein or a scan reading that moves when the drug hits its target. For investors they act like a dashboard gauge, giving early evidence about whether a treatment works, what dose might be right, and how risky or promising a development program is, so they help guide funding and valuation decisions.

biospecimens medical

"bespoke development of assays, expanding from blood plasma to other types of biospecimens."

Biospecimens are physical samples of biological material—such as blood, tissue, urine, saliva, or cells—collected for testing, research, or diagnostics. They matter to investors because access, quality, and legal clearance of these samples are essential for developing and validating drugs, tests, or medical devices; reliable biospecimens reduce scientific risk, speed regulatory approval, and affect a company’s costs and timelines, like having the right raw materials to build a product.

epi-drug medical

"access to high-quality nucleosomes for epi-drug researchers worldwide"

Epi-drugs are medicines that change how genes are switched on or off without altering the underlying DNA sequence, like adjusting a device’s settings rather than replacing its hardware. They can reset abnormal gene activity tied to diseases such as cancer or inflammatory conditions, and matter to investors because their clinical success, regulatory approval, and potential for long-term use can drive significant revenue, partnerships, and sharp stock moves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we have developed over the past 10 years.

We have developed a range of cutting edge controls for our own products, and they should be very useful in a range of research settings. Given our shift to commercialization, we are now opening up these for sale through an online offering.

Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented:

"We are delighted to launch our extensive  range of off-the-shelf recombinant nucleosomes through this easy-to-use website. Manufactured in an ISO 13485 certified facility, delivering exceptional reproducibility and quality control, Volition's nucleosomes are stored and shipped at +4 °C in a glycerol-free buffer, simplifying handling while preserving structural integrity and experimental performance.

"This is a further expansion of our Nu.Q® Discover pillar, where we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug development across multiple therapeutic areas. Some of these pharmaceutical companies have progressed to late stage clinical trials using our assays as pharmacodynamic biomarkers.

"We are excited now to expand our offering with this broad range of ready to use recombinant nucleosomes for research use, and potentially in the future as part of other products.

"We are also in discussion with several pharmaceutical companies for the bespoke development of assays, expanding from blood plasma to other types of biospecimens.

 "We believe our rNuQ™ webshop, where one can browse, click and buy, will provide rapid access to high-quality nucleosomes for epi-drug researchers worldwide and potentially a new source of revenue on our path to commercializing our very large IP portfolio.

"In 2025 we delivered 86% revenue growth for Nu.Q® Discover and anticipate a similar trajectory in 2026."

 

About the rNuQ Shop

With off-the-shelf recombinant nucleosome configurations, this portfolio provides a wide range of  commercial nucleosomes  for research use.

Researchers can select nucleosomes based on histone composition, post-translational modifications (PTMs), and citrullination patterns, with options to tailor key parameters to specific experimental needs.

Unlike many chromatin reagents, Volition nucleosomes are stored and shipped at +4 °C in a glycerol-free buffer, simplifying handling while preserving structural integrity and experimental performance.

The range includes precisely defined PTMs, engineered citrullination patterns, and exclusive H3K18lactylations nucleosomes, some of which are not currently available from any other suppliers.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

rNuQ™, Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

View original content:https://www.prnewswire.com/news-releases/volition-launches-rnuq-webshop-broadening-product-range-302747084.html

SOURCE VolitionRx Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Volition's rNuQ webshop and why does VNRX launch it on April 20, 2026?

The rNuQ webshop is an online store selling ready-to-use recombinant nucleosomes for research use. According to the company, it commercialises controls developed over 10 years, offering ready inventory manufactured in an ISO 13485 facility for reproducible research results.

How did Nu.Q Discover perform financially and what does that mean for VNRX investors?

Nu.Q Discover delivered 86% revenue growth in 2025, signaling commercial traction. According to the company, this growth underpins expansion efforts like the rNuQ webshop and ongoing pharma collaborations, but company-wide guidance for 2026 remains qualitative.

Who are the intended customers for Volition's rNuQ products and how many clients does VNRX currently serve?

Intended customers are epi-drug researchers, pharma and diagnostic companies seeking reproducible controls. According to the company, Volition now serves close to 100 clients worldwide, including many top pharma and diagnostics organizations.

What quality and shipping claims does Volition make about rNuQ products available from VNRX?

rNuQ nucleosomes are manufactured in an ISO 13485 certified facility and shipped at +4 °C. According to the company, they are stored in a glycerol-free buffer to simplify handling while preserving structural integrity and performance.

Will Volition's rNuQ webshop materially increase revenue for VNRX in 2026?

The company describes the webshop as a potential new revenue source but does not provide firm 2026 revenue figures. According to the company, it anticipates a similar growth trajectory for 2026 but offers no quantified guidance.